Metraipolis › archive › dc_5318695faec7

Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity — Europe PMC PMID:41631887

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41631887
DOI
10.1002/advs.202518547
License (as archived)
solo-consultazione
Archived
2026-11-06T04:02:10.301Z
SHA-256 of the archived text
5ee8e32b79dd57a6f4eb6c00741406746dd2325eb15df8e270184ee9b167e997
Stable URL of this page
https://metraipolis.com/documento/dc_5318695faec7

How to cite

Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity — Europe PMC PMID:41631887 — Europe PMC (en), https://europepmc.org/article/MED/41631887 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5318695faec7 (Metraipolis archive dc_5318695faec7, sha256 5ee8e32b79dd57a6f4eb6c00741406746dd2325eb15df8e270184ee9b167e997)
BibTeX
@misc{dc5318695faec7,
  title = {Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity — Europe PMC PMID:41631887},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41631887},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5318695faec7; sha256 5ee8e32b79dd57a6f4eb6c00741406746dd2325eb15df8e270184ee9b167e997},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41631887. Agents can read the archived copy with the MCP tool read_document.